Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
:BCLI
RESEARCH TOOLSreports
Top Page
Brainstorm Cell Therapeutics
(NASDAQ:BCLI)
40Underperform
Positive Factors
Regulatory Environment
Changes to the regulatory landscape seem to support a more favorable environment for NurOwn, with the agency more open to evaluating large datasets and understanding how biomarkers correlate with patient outcomes.
Therapy Validation
There is increasing traction for MSCs within ALS with 5 groups now targeting ALS, providing additional validation for NurOwn – BrainStorm's proprietary cell therapy platform.
Negative Factors
Financial Needs
A substantial amount of capital is expected to be needed to fund the program, which lowers the 12-month price target to $10, from a split-adjusted $30.
Market Conditions
Difficult market conditions, particularly for small/micro-cap stocks, and economic uncertainty continue to pressure broader markets.
Brainstorm Cell Therapeutics (BCLI) vs. S&P 500 (SPY)
Market Cap
$8.22M
Dividend YieldN/A
Average Volume (3M)294.61K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue GrowthN/A
EPS Growth62.35%
CountryUS
Employees27
SectorHealthcare
Sector Strength58
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.32
Shares Outstanding6,522,350
10 Day Avg. Volume157,856
30 Day Avg. Volume294,609
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.75
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Brainstorm Cell Therapeutics Business Overview & Revenue Model
Company DescriptionBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
How the Company Makes MoneyBrainstorm Cell Therapeutics generates revenue through the development and commercialization of its proprietary cellular therapies. The company's primary revenue stream is expected to come from the sale or licensing of NurOwn, pending regulatory approval and successful commercialization. Additionally, Brainstorm may engage in strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other stakeholders to advance its clinical programs and expand its market reach. These partnerships may provide upfront payments, milestone payments, and royalties, contributing to the company's earnings. Other potential revenue sources include government grants and funding from non-profit organizations that support research in neurodegenerative diseases.
Brainstorm Cell Therapeutics Financial Statement Overview
Summary
Brainstorm Cell Therapeutics faces significant financial challenges with negative profitability, weak balance sheet stability, and reliance on external financing. The company needs substantial improvements in revenue generation and cost management to enhance its financial health.Income Statement
The company has consistently generated negative net income and EBIT margins, with minimal to no revenue growth over the past years. Despite a small revenue in the TTM period, margins remain negative, indicating ongoing operational challenges.30
Negative
Balance Sheet
The company's balance sheet shows negative stockholders' equity and high liabilities relative to assets, indicating financial instability. The high debt-to-equity ratio further suggests potential insolvency risks.20
Very Negative
Cash Flow
The company has consistently negative operating cash flow, with no positive free cash flow growth. The cash flow from financing indicates reliance on external funding, which may not be sustainable long-term.25
Negative
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | -366.00K | Gross Profit |
| -265.00K | -285.00K | -260.00K | -219.00K | -732.00K | EBIT |
| -21.44M | -24.82M | -24.54M | -31.68M | -23.00M | EBITDA |
| -16.93M | -23.99M | -24.28M | -31.46M | -23.09M | Net Income Common Stockholders |
| -17.19M | -23.73M | -24.38M | -31.94M | -23.50M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.30M | 2.98M | 22.09M | 41.94M | 569.00K | Total Assets |
| 4.21M | 8.45M | 29.28M | 51.26M | 6.53M | Total Debt |
| 672.00K | 4.09M | 5.08M | 7.22M | 2.37M | Net Debt |
| -628.00K | 3.32M | -13.78M | -30.61M | 1.83M | Total Liabilities |
| 9.07M | 11.47M | 9.94M | 15.79M | 18.76M | Stockholders Equity |
| -4.86M | -3.02M | 19.34M | 35.46M | -12.22M |
| Cash Flow | Free Cash Flow | |||
| -20.48K | -19.35M | -26.59M | -35.57M | -11.72M | Operating Cash Flow |
| -20.46M | -19.32M | -26.27M | -35.19M | -11.25M | Investing Cash Flow |
| 2.19M | 998.00K | 323.00K | -4.45M | 5.62M | Financing Cash Flow |
| 18.98M | 238.00K | 6.97M | 76.94M | 5.22M |
Brainstorm Cell Therapeutics Technical Analysis
Neutral
1.26
Price Trends
1.30
Negative
1.63
Negative
2.47
Negative
Market Momentum
-0.05
Negative
52.64
Neutral
69.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCLI, the sentiment is Neutral. The current price of 1.26 is above the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.30, and below the 200-day MA of 2.47, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 52.64 is Neutral, neither overbought nor oversold. The STOCH value of 69.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BCLI.
Brainstorm Cell Therapeutics Risk Analysis
Brainstorm Cell Therapeutics disclosed 64 risk factors in its most recent earnings report. Brainstorm Cell Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Brainstorm Cell Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% | |
42 Neutral | $7.35M | ― | -184.99% | ― | -1.54% | -7.20% | |
41 Neutral | $6.64M | 49.73 | 0.08% | ― | -100.00% | ― | |
40 Underperform | $8.22M | ― | 234.90% | ― | ― | 62.35% | |
34 Underperform | $5.91M | ― | -453.39% | ― | ― | -26.02% |
* Healthcare Sector Average
Performance Comparison
BCLI
Brainstorm Cell Therapeutics
1.26
-4.44
-77.89%
GTBP
GT Biopharma
2.33
-0.97
-29.39%
GNPX
Genprex
0.29
-2.15
-88.11%
APM
Aptorum Group
0.93
-4.65
-83.33%
LYRA
Lyra Therapeutics
0.11
-3.92
-97.27%
CDT
Conduit Pharmaceuticals
0.54
-299.46
-99.82%
Brainstorm Cell Therapeutics Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: 5.88%|
Next Earnings Date:May 19, 2025
Earnings Call Sentiment Neutral
The call highlighted significant regulatory and strategic advancements, cost reduction measures, and commitment from the leadership team. However, it also acknowledged delays in the Phase 3b trial initiation, financial constraints, and skepticism about NurOwn's efficacy. The company is focused on overcoming these challenges with strategic funding and partnerships.Q4-2024 Updates
Positive Updates
Regulatory Advancements
Secured a special protocol assessment with the FDA, significantly derisking the regulatory pathway for NurOwn, the ALS treatment.
Strategic Partnerships for Trial Execution
Partnership with IQVIA for managing the Phase 3b trial and with Pluri Inc. for GMP compliant production of NurOwn.
Cost Reduction Achievements
Research and development expenses reduced from $10.7 million in 2023 to $4.7 million in 2024. General and administrative expenses also decreased from $10.7 million in 2023 to $7 million in 2024.
Financial Strategy and Inducement
Raised approximately $1.64 million through a warrant inducement agreement. Actively pursuing multiple funding avenues including licensing non-core assets and exploring non-dilutive financing opportunities.
Commitment from Leadership
Senior leadership and staff have taken salary reductions or worked without compensation to advance the trial.
Negative Updates
Delays in Phase 3b Trial Initiation
Perceived delays in initiating the Phase 3b trial due to regulatory and financial constraints. Complexity of trial preparation is cited as a reason.
Financial Constraints and Net Loss
Net loss for 2024 was approximately $11.6 million compared to $17.2 million in 2023. Cash and cash equivalents reduced from $1.5 million in 2023 to $0.4 million in 2024.
Skepticism About Efficacy
Continued skepticism from analysts and investors regarding the efficacy of NurOwn, requiring robust data to validate the treatment.
Company Guidance
In the recent earnings call, BrainStorm Cell Therapeutics provided detailed guidance on their strategic focus and financial outlook for 2025. The company is prioritizing the execution of the critical Phase 3b trial of NurOwn, their investigational treatment for ALS, with the aim of confirming its potential to significantly slow disease progression in early-stage patients. They have secured a special protocol assessment from the FDA, which derisks the regulatory pathway, and are in active negotiations with approximately 15 leading clinical centers in the U.S. to finalize clinical trial agreements. The company anticipates that they will need approximately $20 million to $30 million annually to fund the trial, and they are actively pursuing multiple funding avenues, including licensing non-core assets and exploring non-dilutive financing opportunities. Additionally, BrainStorm has partnered with IQVIA for trial execution and has contracted with Pluri Inc. for clinical manufacturing. As of December 2024, the company's cash, cash equivalents, and restricted cash stood at approximately $0.4 million, compared to $1.5 million at the end of 2023, and they have announced a warrant inducement agreement expected to raise approximately $1.64 million in gross proceeds.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.